<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-511" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Poly-L-Lactic Acid</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sickles </surname>
            <given-names>Christine K.</given-names>
          </name>
          <aff>Lewis Gale Hospital Montgomery</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nassereddin</surname>
            <given-names>Ali</given-names>
          </name>
          <aff>WakeMed Health and Hospitals</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gross</surname>
            <given-names>Gary P.</given-names>
          </name>
          <aff>Lewis Gale Hospital Montgomery</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Christine Sickles declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ali Nassereddin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gary Gross declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-511.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Poly-L-lactic acid is an injectable implant renowned for its absorbable and semi-permanent nature, exhibiting the unique capability to restore volume and prompt collagen formation gradually. With FDA approval specifically for addressing facial fat loss linked to antiretroviral therapy-induced lipoatrophy in HIV patients, this implant is effective for correcting nasolabial fold deficiencies and various facial wrinkles in immunocompetent individuals. Beyond its approved applications, poly-L-lactic acid is used off-label in augmenting areas such as cheeks, hands, neck, thighs, gluteal enhancement, and rectifying chest wall deformities like pectus excavatum or thoracic deformities post-surgical procedures.</p>
        <p>This activity discusses poly-L-lactic acid's mode of action, modes of administration, potential adverse events, eligible patient populations, and monitoring protocols. Emphasizing the pivotal role of the interprofessional team in managing patients undergoing poly-L-lactic acid treatment, this educational initiative provides a thorough understanding of this cutting-edge intervention, fostering enhanced patient care and outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate candidates for poly-L-lactic acid injections based on patient-specific factors, such as age, skin condition, and desired aesthetic outcomes.</p></list-item><list-item><p>Screen patients for contraindications, potential allergies, and medical history that may impact poly-L-lactic acid's safe and effective use.</p></list-item><list-item><p>Develop&#x000a0;effective communication with patients, providing detailed information about poly-L-lactic acid, its expected outcomes, potential side effects, and the importance of realistic expectations.</p></list-item><list-item><p>Implement strategies&#x000a0;with dermatologists, plastic surgeons, and other healthcare professionals to ensure comprehensive care and an interdisciplinary approach to patients undergoing poly-L-lactic acid treatments.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=511&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=511">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-511.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Poly-L-lactic acid (PLLA) is an absorbable, semi-permanent, injectable implant that can restore volume and gradually stimulate collagen formation.&#x000a0;Poly-L-lactic&#x000a0;acid is FDA-approved for correcting facial fat loss associated with antiretroviral therapy-induced lipoatrophy in HIV patients. PLLA is FDA-approved for immunocompetent people to correct nasolabial fold deficiencies and other facial wrinkles.</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>PLLA has been used off-label to enhance the cheeks, hands, neck, and thighs, gluteal enhancement, and chest wall deformities, such as pectus excavatum or thoracic deformities secondary to surgical procedures.<xref ref-type="bibr" rid="article-511.r1">[1]</xref><xref ref-type="bibr" rid="article-511.r2">[2]</xref>&#x000a0;Poly-L-lactic acid has been reported to improve "step-off" chest wall deformities after mastectomy and implant reconstruction, suggesting that this product can also help improve breast abnormalities. For maximal correction, a series of injections is recommended at 3 to 6-week intervals. The degree of lipoatrophy correction is based on the number of sessions, not the volume injected at each session.<xref ref-type="bibr" rid="article-511.r3">[3]</xref>&#x000a0;PLLA is also used for non-facial body treatments to address skin laxity, reduce cellulite, and treat scars.<xref ref-type="bibr" rid="article-511.r4">[4]</xref></p>
        <p>Recent&#x000a0;research suggested the role of PLLA in meningomyelocele (MMC). Poly-L-lactic&#x000a0;acid (PLLA) played a crucial role in the novel patch design for MMC repair conducted by researchers. By blending PLLA with poly (&#x003b5;-caprolactone), the researchers aimed to address the limitations of existing patch materials. The importance of PLLA was underscored by its favorable degradation behavior and ability to maintain structural integrity throughout the 16-week study period. This emphasized PLLA's potential as a critical component in creating a superior alternative for meningomyelocele repair, offering promising possibilities for improved patient outcomes. Additional animal and human studies are required.<xref ref-type="bibr" rid="article-511.r5">[5]</xref></p>
      </sec>
      <sec id="article-511.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Injection of poly-L-lactic acid into the deep dermis or subcutaneous tissue may immediately augment the treated tissue. This is a temporary but&#x000a0;immediate response due to tissue edema and fluid from the reconstitution of the product. This usually resolves within 2 to 3 days after injection.</p>
        <p>Once the carrier substance is absorbed, the poly-L-lactic acid particles induce an inflammatory response through phagocytosis by tissue macrophages. This is a similar process to suture reabsorption in the skin. The inflammatory response breaks down the poly-L-lactic acid into lactic acid monomers.&#x000a0;These are&#x000a0;then metabolized to carbon dioxide and water while stimulating the production of new collagen type-I fibers in the skin. Approximately half of the product is digested within&#x000a0;6 months. The duration of action is 12 to 24 months.<xref ref-type="bibr" rid="article-511.r6">[6]</xref><xref ref-type="bibr" rid="article-511.r7">[7]</xref><xref ref-type="bibr" rid="article-511.r8">[8]</xref>&#x000a0;Neutrophils, macrophages, and fibroblasts play a role in enzymatic degradation. These cells secrete acid phosphatase and lactate dehydrogenase, which actively enhance the degradation of PLLA.<xref ref-type="bibr" rid="article-511.r9">[9]</xref></p>
      </sec>
      <sec id="article-511.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Poly-L-lactic acid is available as microparticles of lyophilized, alpha-hydroxy acid polymers similar in structure to the polyglactin 910 suture material manufactured&#x000a0;in powder form. Poly-L-lactic acid comes in a carton containing&#x000a0;2 vials. Each vial contains 367.5 g of product and is reconstituted with 4 mL of sterile water and 1 mL of lidocaine, producing a 5 mL suspension of 4.45% poly-L-lactic acid. Higher dilution volumes can be used.</p>
        <p>Once diluted, it should be allowed to stand undisturbed for 2 to 4 hours and swirled immediately before injection to ensure an even suspension of particles. Some injectors recommend dilution 24 to 72 hours before injection to allow appropriate powder saturation.<xref ref-type="bibr" rid="article-511.r10">[10]</xref><xref ref-type="bibr" rid="article-511.r11">[11]</xref>&#x000a0;The vials are intended for single-patient use only&#x000a0;and should not&#x000a0;be reused or resterilized. If the package or vial is opened or damaged, it should not be used.</p>
        <p>The product does not require refrigeration once reconstituted. The poly-L-lactic acid is placed into the deep dermis or subcutaneous tissue using a 26-gauge needle, roughly&#x000a0;1 vial per side of the face. Various injection techniques, including linear threading, depot injection in small volumes, and cross-hatching, can be used. Massage should be performed during and after the injection to ensure an even distribution of the material. The patient should apply ice packs to the treatment areas to reduce erythema and swelling.<xref ref-type="bibr" rid="article-511.r12">[12]</xref><xref ref-type="bibr" rid="article-511.r13">[13]</xref></p>
        <p>Overcorrecting the nasolabial fold contour defect by overfilling should be avoided, as the depression is expected to gradually improve over several weeks following the injection when the effects of PLLA become evident.<xref ref-type="bibr" rid="article-511.r14">[14]</xref>&#x000a0;The cross-fanning injection technique has been employed in research studies involving patients with HIV-related facial lipoatrophy and immune-competent patients undergoing treatment for aging-related facial lipoatrophy.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;The safety and efficacy of poly-L-lactic acid (PLLA) have not been systematically evaluated in pregnant patients.<xref ref-type="bibr" rid="article-511.r15">[15]</xref></p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;PLLA has not been evaluated in lactation.<xref ref-type="bibr" rid="article-511.r16">[16]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;The safety and efficacy of poly-L-lactic acid have not been established in individuals&#x000a0;younger than 18.</p>
        <p><bold>Older patients</bold>:&#x000a0;Collagen production diminishes with age and sun exposure, leading to visible wrinkles. PLLA, a dermal filler, is injected into the deep skin layer to stimulate collagen production. PLLA particles initially fill the wrinkles and gradually degrade, stimulating the body's production of new collagen.</p>
      </sec>
      <sec id="article-511.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Acute injection site reaction is the most common adverse effect of administering this product. This can manifest as erythema, swelling, or bruising that can take up to a&#x000a0;week to heal.&#x000a0;Optimal administration of poly-L-lactic&#x000a0;acid (PLLA)&#x000a0;involves&#x000a0;deep dermal injection to minimize the incidence of adverse events.&#x000a0;The aseptic technique must be strictly adhered to during poly-L-lactic&#x000a0;acid sessions to reduce the risk of infection.&#x000a0;Immediate application of ice compression following the injection is recommended while decreasing direct exposure to sunlight.<xref ref-type="bibr" rid="article-511.r17">[17]</xref></p>
        <p>Poly-L-lactic acid is a foreign substance. Therefore, it risks a hypersensitivity reaction upon injection into the skin. Patients should remove all makeup, and the skin should be adequately prepped before injection to minimize the introduction of additional foreign particles. Skin testing can be performed before treatment.</p>
        <p>Post-treatment nodules with granuloma formation can occur with an injection of this product.<xref ref-type="bibr" rid="article-511.r18">[18]</xref> The risk is thought to be due to lower dilution volumes, and studies have shown that a decreased risk exists when dilution of volumes of 7 mL or more is used. A post-injection massage is recommended to be performed for 5 minutes at a time,&#x000a0;5 times a day for&#x000a0;5 days after injection, and has been anecdotally recommended to help minimize the occurrence of nodules. Injectors can also place smaller aliquots of the product deeper in the skin to help reduce this risk.</p>
        <p>Several treatments&#x000a0;are available if the patient experiences nodule formation. Early-onset lesions can be treated with subcision or injected with sterile water. Later-onset nodules can be treated with intralesional triamcinolone up to 40 mg/mL or 5-fluorouracil 2% or 5% combined with a low-dose oral tetracycline antibiotic. There are some reports that oral prednisone may be used to help suppress the formation of nodules.</p>
        <p>Inappropriate placement of this product in the skin can lead to lumpiness or visibility of the filler through the skin. Post-treatment massage to the area can help decrease this risk.</p>
        <p>Post-procedural infection is rare but can occur. The skin should be prepped with an antiseptic such as alcohol, followed by chlorhexidine or chloroxylenol. Some injectors inquire about a history of HSV and provide adequate&#x000a0;prevention of antivirals up to 2 days before and&#x000a0;2 days after treatment if augmentation is performed on or around the lip.&#x000a0;</p>
        <p>Edema has been documented in correlation with erythema, nociception, and a sensation of heat. The symptoms were predominantly transient and exhibited no substantial detriment to the individual's quality of daily life. Treatment with corticosteroids, antihistamines, and anti-inflammatory drugs may be required. The resolution typically occurs within 7&#x000a0;to 10 days.<xref ref-type="bibr" rid="article-511.r19">[19]</xref>&#x000a0;Paraffinoma of lower eyelids as a complication of PLLA has been reported.<xref ref-type="bibr" rid="article-511.r20">[20]</xref></p>
        <p>The most feared complication of an injectable product is skin necrosis due to the cannulation of the product into a vessel with subsequent embolization or compression of a vessel from excessive volume.<xref ref-type="bibr" rid="article-511.r21">[21]</xref>&#x000a0;Healthcare professionals should thoroughly understand the anatomy of the treatment area and be aware of any potential danger zones. Injection of low volumes over multiple treatment sessions should be used whenever possible. Aspiration should be performed before injecting the product into the tissue. Methods to promote vasodilation should be employed in the event of vascular compromise. The area should be treated with a warm compress and topical nitroglycerin to promote vasodilation.</p>
        <p><bold>Drug</bold>-<bold>Drug Interactions</bold></p>
        <p>Injection site reaction increases if the patient takes a blood-thinning agent, such as aspirin, warfarin, clopidogrel, apixaban, rivaroxaban, and dabigatran. Clinicians should&#x000a0;carefully review the patient's medication list and counsel them regarding the increased risk. Patients with coagulation disorders or those receiving anticoagulant therapy are at increased risk of hematoma formation and bleeding at the injection site during poly-L-lactic&#x000a0;acid treatment.&#x000a0;Smoking impairs the healing outcome of guided tissue regeneration treatment of intra-bony defects.<xref ref-type="bibr" rid="article-511.r22">[22]</xref></p>
        <p>No clinical studies have been performed to&#x000a0;analyze the interactions of PLLA with local anesthetics, co-administered drugs, or concurrent devices.</p>
        <p>Mixing poly-L-lactic&#x000a0;acid with other dermal filler products is not recommended.</p>
        <p>
<bold>Imaging Interference</bold>
</p>
        <p>The radiopacity of poly-L-lactic&#x000a0;acid in humans remains uncertain; microparticles may be detectable on specific imaging modalities.<xref ref-type="bibr" rid="article-511.r23">[23]</xref></p>
      </sec>
      <sec id="article-511.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>A known allergy to poly-L-lactic acid or any components (carboxymethylcellulose&#x000a0;or non-pyrogenic mannitol)&#x000a0;represents an absolute contraindication to treatment. Poly-L-lactic acid (PLLA) is contraindicated for use in patients with a documented history of or a predisposition to keloid formation or hypertrophic scarring.<xref ref-type="bibr" rid="article-511.r24">[24]</xref></p>
        <p>
<bold>Box Warnings</bold>
</p>
        <p>PLLA filler injection must not be injected into blood vessels due to potential complications such as vessel occlusion, ischemia, or infarction.</p>
        <p>Rare and severe adverse events due to the IV injection of soft tissue fillers in the face have been reported, including temporary or permanent vision impairment, blindness, and cerebral ischemia. If a patient exhibits symptoms such as changes in vision, signs of a stroke, skin paleness, or unusual pain during or after the procedure, the injection should be immediately stopped. Evaluation by a specialist may be necessary.<xref ref-type="bibr" rid="article-511.r18">[18]</xref></p>
        <p>PLLA filler injection in specific sites with active inflammatory processes or infections should be postponed until the inflammatory condition is resolved and controlled.</p>
        <p>Delayed inflammatory reactions to dermal fillers have been reported following vaccination with mRNA COVID-19 vaccines.<xref ref-type="bibr" rid="article-511.r25">[25]</xref><xref ref-type="bibr" rid="article-511.r26">[26]</xref></p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>The safety and effectiveness of poly-L-lactic&#x000a0;acid (PLLA) in various dosages, frequencies, injection sites, techniques, or in conjunction with&#x000a0;other dermal filler injections have not undergone evaluation.</p>
        <p>Using poly-L-lactic&#x000a0;acid (PLLA) in the lips&#x000a0;requires caution;&#x000a0;clinicians should not&#x000a0;inject it into the vermillion of the lip.</p>
        <p>Care should be exercised when administering poly-L-lactic acid (PLLA) to patients with thin skin.<xref ref-type="bibr" rid="article-511.r17">[17]</xref></p>
        <p>Poly-L-lactic acid (PLLA) injections in the peri-orbital region can cause nodules and papules.<xref ref-type="bibr" rid="article-511.r27">[27]</xref></p>
        <p>Used syringes and needles containing poly-L-lactic&#x000a0;acid (PLLA) are considered biohazardous and should be handled and disposed of by established medical practices and relevant regulations.</p>
        <p>If laser treatment or other procedures inducing an active dermal response are contemplated following poly-L-lactic&#x000a0;acid (PLLA) treatment, there is a potential risk of an inflammatory reaction at the implant site, particularly if the skin has not completely healed.<xref ref-type="bibr" rid="article-511.r28">[28]</xref></p>
      </sec>
      <sec id="article-511.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>All patients should be assessed before treatment for facial asymmetry and volume differences. Documentation of any preexisting scars and inquire about a history of keloid formation is essential. All patients should receive baseline photographs and return for assessment 2 to 4 weeks after injection. Patients should be advised to avoid unnecessary herbal medications and supplements to decrease the risk of bruising. Anticoagulants should not be discontinued.&#x000a0;</p>
        <p>The FDA&#x000a0;has warned&#x000a0;against using non-approved needle-free devices for injecting dermal fillers. Only FDA-approved fillers should be prescribed, using a syringe and needle or cannula. Healthcare providers should caution patients against purchasing needle-free devices online. Adverse effects from these devices should be reported to the FDA's MedWatch system.<xref ref-type="bibr" rid="article-511.r29">[29]</xref></p>
      </sec>
      <sec id="article-511.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There is no antidote to dissolve poly-L-lactic acid. In a vascular compromise, methods to promote vasodilation should be employed. To promote vasodilation, the area should be treated with warm compresses and topical nitroglycerin.&#x000a0;</p>
      </sec>
      <sec id="article-511.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Poly-L-lactic acid is an absorbable, semi-permanent, injectable implant that can gradually restore volume and stimulate collagen formation.&#x000a0;The drug is FDA-approved for correcting facial fat loss associated with antiretroviral therapy-induced lipoatrophy in HIV patients.</p>
        <p>Poly-L-lactic acid (PLLA) should be administered exclusively by trained healthcare professionals with comprehensive training. While this dermal filler is usually only injected by dermatologists and plastic surgeons, primary care providers and advanced practice practitioners should know which patients may benefit from it.</p>
        <p>Before treatment, healthcare practitioners should thoroughly discuss potential risks and complications with patients. In addition, the healthcare team should advise patients to minimize sun exposure and avoid ultraviolet light exposure in the treated area.</p>
        <p>Nurses and pharmacists should monitor the patients for adverse effects. Patients&#x000a0;require education regarding the drug's adverse effects, potential complications, and durability. Open communication between&#x000a0;all interprofessional team members and patients can lead to&#x000a0;optimal benefits from poly-L-lactic acid when indicated.</p>
      </sec>
      <sec id="article-511.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=511&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=511">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/511/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=511">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-511.s11">
        <title>References</title>
        <ref id="article-511.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eglin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grijpma</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Richards</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Osteogenic magnesium incorporated into PLGA/TCP porous scaffold by 3D printing for repairing challenging bone defect.</article-title>
            <source>Biomaterials</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>197</volume>
            <fpage>207</fpage>
            <page-range>207-219</page-range>
            <pub-id pub-id-type="pmid">30660996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ibrahim</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ionta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Depina</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Petrell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Arndt</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Dover</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Safety of Laser-Assisted Delivery of Topical Poly-L-Lactic Acid in the Treatment of Upper Lip Rhytides: A Prospective, Rater-Blinded Study.</article-title>
            <source>Dermatol Surg</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>45</volume>
            <issue>7</issue>
            <fpage>968</fpage>
            <page-range>968-974</page-range>
            <pub-id pub-id-type="pmid">30608292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tung</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Injection technique in neurotoxins and fillers: Indications, products, and outcomes.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>79</volume>
            <issue>3</issue>
            <fpage>423</fpage>
            <page-range>423-435</page-range>
            <pub-id pub-id-type="pmid">30119866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christen</surname>
                <given-names>MO</given-names>
              </name>
            </person-group>
            <article-title>Collagen Stimulators in Body Applications: A Review Focused on Poly-L-Lactic Acid (PLLA).</article-title>
            <source>Clin Cosmet Investig Dermatol</source>
            <year>2022</year>
            <volume>15</volume>
            <fpage>997</fpage>
            <page-range>997-1019</page-range>
            <pub-id pub-id-type="pmid">35761856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tatu</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Oria</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Peiro</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>CY</given-names>
              </name>
            </person-group>
            <article-title>Biodegradation of poly(L-lactic acid) and poly(&#x003b5;-caprolactone) patches by human amniotic fluid in an in-vitro simulated fetal environment.</article-title>
            <source>Sci Rep</source>
            <year>2022</year>
            <month>Mar</month>
            <day>10</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>3950</fpage>
            <pub-id pub-id-type="pmid">35273223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herrmann</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Schulman</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Grekin</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Biochemistry, Physiology, and Tissue Interactions of Contemporary Biodegradable Injectable Dermal Fillers.</article-title>
            <source>Dermatol Surg</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>44 Suppl 1</volume>
            <fpage>S19</fpage>
            <page-range>S19-S31</page-range>
            <pub-id pub-id-type="pmid">29994947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hotta</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Attention to Infection Prevention in Medical Aesthetic Clinics.</article-title>
            <source>Plast Surg Nurs</source>
            <year>2018</year>
            <season>Jan/Mar</season>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-24</page-range>
            <pub-id pub-id-type="pmid">29494408</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pascali</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Quarato</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Carinci</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Filling Procedures for Lip and Perioral Rejuvenation: A Systematic Review.</article-title>
            <source>Rejuvenation Res</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>553</fpage>
            <page-range>553-559</page-range>
            <pub-id pub-id-type="pmid">29911505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>da Silva</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kaduri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Poley</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Adir</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Krinsky</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shainsky-Roitman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schroeder</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Biocompatibility, biodegradation and excretion of polylactic acid (PLA) in medical implants and theranostic systems.</article-title>
            <source>Chem Eng J</source>
            <year>2018</year>
            <month>May</month>
            <day>15</day>
            <volume>340</volume>
            <fpage>9</fpage>
            <page-range>9-14</page-range>
            <pub-id pub-id-type="pmid">31384170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fallacara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Manfredini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Durini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vertuani</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Hyaluronic Acid Fillers in Soft Tissue Regeneration.</article-title>
            <source>Facial Plast Surg</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>87</fpage>
            <page-range>87-96</page-range>
            <pub-id pub-id-type="pmid">28226376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Winslow</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Filling the Midface: Injectables.</article-title>
            <source>Facial Plast Surg</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>473</fpage>
            <page-range>473-9</page-range>
            <pub-id pub-id-type="pmid">27680518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sadick</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Arruda</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The Use of Poly-L-Lactic Acid in the Abdominal Area.</article-title>
            <source>Dermatol Surg</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>43</volume>
            <issue>2</issue>
            <fpage>313</fpage>
            <page-range>313-315</page-range>
            <pub-id pub-id-type="pmid">27598451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Lorenc</surname>
                <given-names>ZP</given-names>
              </name>
            </person-group>
            <article-title>Synthetic Fillers for Facial Rejuvenation.</article-title>
            <source>Clin Plast Surg</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>497</fpage>
            <page-range>497-503</page-range>
            <pub-id pub-id-type="pmid">27363763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mest</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Humble</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Review and Evaluation of Treatment Procedures Using Injectable Poly-L-Lactic Acid in the Treatment of Human Immunodeficiency Virus-associated Facial Lipoatrophy.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>3</volume>
            <issue>12</issue>
            <fpage>43</fpage>
            <page-range>43-9</page-range>
            <pub-id pub-id-type="pmid">21203355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trivedi</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Kroumpouzos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Murase</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>A review of the safety of cosmetic procedures during pregnancy and lactation.</article-title>
            <source>Int J Womens Dermatol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-10</page-range>
            <pub-id pub-id-type="pmid">28492048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koh</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Oon</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>New changes in pregnancy and lactation labelling: Review of dermatologic drugs.</article-title>
            <source>Int J Womens Dermatol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>216</fpage>
            <page-range>216-226</page-range>
            <pub-id pub-id-type="pmid">31700976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>YR</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>HB</given-names>
              </name>
            </person-group>
            <article-title>Application of Nonsurgical Modalities in Improving Facial Aging.</article-title>
            <source>Int J Dent</source>
            <year>2022</year>
            <volume>2022</volume>
            <fpage>8332631</fpage>
            <pub-id pub-id-type="pmid">35251183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beauvais</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ferneini</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Complications and Litigation Associated With Injectable Facial Fillers: A Cross-Sectional Study.</article-title>
            <source>J Oral Maxillofac Surg</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>78</volume>
            <issue>1</issue>
            <fpage>133</fpage>
            <page-range>133-140</page-range>
            <pub-id pub-id-type="pmid">31493376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nooreyezdan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Nonvascular Complications of Injectable Fillers-Prevention and Management.</article-title>
            <source>Indian J Plast Surg</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>335</fpage>
            <page-range>335-343</page-range>
            <pub-id pub-id-type="pmid">33500603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Late-Onset Complication of Fillers: Paraffinoma of the Lower Eyelids Clinically Mimicking Xanthelasma.</article-title>
            <source>Ann Dermatol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>28</volume>
            <issue>6</issue>
            <fpage>753</fpage>
            <page-range>753-756</page-range>
            <pub-id pub-id-type="pmid">27904276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rayess</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Svider</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Hanba</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>DeJoseph</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Carron</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zuliani</surname>
                <given-names>GF</given-names>
              </name>
            </person-group>
            <article-title>A Cross-sectional Analysis of Adverse Events and Litigation for Injectable Fillers.</article-title>
            <source>JAMA Facial Plast Surg</source>
            <year>2018</year>
            <month>May</month>
            <day>01</day>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>207</fpage>
            <page-range>207-214</page-range>
            <pub-id pub-id-type="pmid">29270603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stavropoulos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mardas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Herrero</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Karring</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Smoking affects the outcome of guided tissue regeneration with bioresorbable membranes: a retrospective analysis of intrabony defects.</article-title>
            <source>J Clin Periodontol</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>31</volume>
            <issue>11</issue>
            <fpage>945</fpage>
            <page-range>945-50</page-range>
            <pub-id pub-id-type="pmid">15491308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warden</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Chooljian</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Ten-year magnetic resonance imaging follow-up of bioabsorbable poly-L-lactic acid interference screws after anterior cruciate ligament reconstruction.</article-title>
            <source>Arthroscopy</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>370.e1</fpage>
            <page-range>370.e1-3</page-range>
            <pub-id pub-id-type="pmid">18308192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sadove</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Injectable poly-L: -lactic acid: a novel sculpting agent for the treatment of dermal fat atrophy after severe acne.</article-title>
            <source>Aesthetic Plast Surg</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>113</fpage>
            <page-range>113-6</page-range>
            <pub-id pub-id-type="pmid">18923863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beamish</surname>
                <given-names>IV</given-names>
              </name>
              <name>
                <surname>Bogoch</surname>
                <given-names>II</given-names>
              </name>
              <name>
                <surname>Carr</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Delayed inflammatory reaction to dermal fillers after COVID-19 vaccination: a case report.</article-title>
            <source>CJEM</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>444</fpage>
            <page-range>444-446</page-range>
            <pub-id pub-id-type="pmid">35294771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bachour</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bekkenk</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Rustemeyer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kadouch</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Late inflammatory reactions in patients with soft tissue fillers after SARS-CoV-2 infection and vaccination: A systematic review of the literature.</article-title>
            <source>J Cosmet Dermatol</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>1361</fpage>
            <page-range>1361-1368</page-range>
            <pub-id pub-id-type="pmid">35150192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lowe</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Maxwell</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Lowe</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patnaik</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Injectable poly-l-lactic acid: 3 years of aesthetic experience.</article-title>
            <source>Dermatol Surg</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>35 Suppl 1</volume>
            <fpage>344</fpage>
            <page-range>344-9</page-range>
            <pub-id pub-id-type="pmid">19207324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szustakiewicz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kryszak</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dzienny</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Po&#x0017a;niak</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tikhomirov</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoppe</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Szymczyk-Zi&#x000f3;&#x00142;kowska</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tylus</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Grzymaj&#x00142;o</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gadomska-Gajadhur</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anto&#x00144;czak</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Cytotoxicity Study of UV-Laser-Irradiated PLLA Surfaces Subjected to Bio-Ceramisation: A New Way towards Implant Surface Modification.</article-title>
            <source>Int J Mol Sci</source>
            <year>2021</year>
            <month>Aug</month>
            <day>05</day>
            <volume>22</volume>
            <issue>16</issue>
            <pub-id pub-id-type="pmid">34445136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-511.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aschenbrenner</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>FDA Warns Against Using Needle-Free Injection Devices For Dermal Fillers.</article-title>
            <source>Am J Nurs</source>
            <year>2022</year>
            <month>Feb</month>
            <day>01</day>
            <volume>122</volume>
            <issue>2</issue>
            <fpage>24</fpage>
            <page-range>24-25</page-range>
            <pub-id pub-id-type="pmid">35085145</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
